CLEC10A and cancer: Especially, the macrophage galactose-type lectin receptor (MGL, CD301) has a high preference for tumor-associated glycans and can particularly recognize terminal N-acetylgalactosamine (α- or β-linked GalNAc) residues, as found for instance in the truncated O-glycan Tn antigen (αGalNAc-Ser/Thr), which is predominantly expressed on many cancer cells, including, colorectal, cervical and breast cancer cells, and has been associated with metastasis and poor prognosis (2–5).